STAGE III OVARIAN CANCER AJCC V8
Clinical trials for STAGE III OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug (BAY 1895344) combined with standard chemotherapy for people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, ovarian,…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Immunotherapy drug shows promise for hard-to-treat cancers with genetic flaws
Disease control OngoingThis study tests the drug pembrolizumab in people with advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. About 21 adults with metastatic or recurrent cancer took part. Pembrolizu…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for rare ovarian cancer: could hormone therapy replace chemo?
Disease control OngoingThis study tests whether the hormone therapy letrozole alone works as well as chemotherapy (paclitaxel and carboplatin) followed by letrozole for people with stage II-IV low-grade serous ovarian, fallopian tube, or peritoneal cancer. About 450 participants will be randomly assign…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tested the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they had surgery. The goal was to see if taking olaparib for two cycles could shrink tumors or stop them from growing. Olaparib works…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:55 UTC
-
Online support for cancer fear: study withdrawn before it began
Knowledge-focused TerminatedThis study was designed to see if a virtual mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer coming back or getting worse. The program would have been compared to standard educational materials. However, the study w…
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:17 UTC
-
Can we predict who will get nerve damage from chemo?
Knowledge-focused OngoingThis study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …
Matched conditions: STAGE III OVARIAN CANCER AJCC V8
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:04 UTC